What is the likely diagnosis and recommended management for a patient whose chest CT shows few small air‑space opacifications with surrounding centrilobular nodules in the right upper lobe and left lower lobe, volume loss in the medial segment of the right middle lobe, mild cylindrical bronchiectasis in the bilateral lower lobes and right upper lobe posterior segment, and mildly enlarged pre‑/paratracheal and carinal mediastinal lymph nodes?

CT Chest Interpretation: Likely Hypersensitivity Pneumonitis with Bronchiectasis

The CT findings of centrilobular nodules with air-space opacifications, mosaic attenuation (volume loss), bronchiectasis, and mediastinal lymphadenopathy are most consistent with hypersensitivity pneumonitis (HP), and you should immediately pursue detailed exposure history (birds, mold, occupational antigens) and consider bronchoscopy with BAL and transbronchial biopsy to confirm the diagnosis and guide treatment. 1, 2

Radiologic Pattern Analysis

The CT demonstrates several key features that point toward HP:

Centrilobular Nodules with Ground-Glass Opacity

• These are highly characteristic of HP when diffusely distributed 1, 2
• The combination of centrilobular nodules with air-space opacifications (ground-glass opacity) creates what guidelines describe as "profuse poorly defined centrilobular nodules of ground-glass opacity" 1
• In a nonsmoker, diffuse ground-glass centrilobular nodules are highly suggestive of HP 1
• This pattern reflects small airway disease with surrounding pneumonitis 2

Volume Loss and Mosaic Attenuation

• The volume loss in the right middle lobe represents air-trapping, a hallmark of small airway obstruction in HP 1, 2
• This creates mosaic attenuation on inspiratory images—areas of varying lung density that indicate bronchiolar obstruction 2
• The combination of centrilobular nodules with air-trapping has 100% positive predictive value for HP 1

Bronchiectasis Pattern

• Mild cylindrical bronchiectasis in multiple segments suggests chronic/fibrotic HP rather than acute HP 1, 2
• The distribution (bilateral lower lobes and right upper lobe) is consistent with HP's variable distribution pattern 1
• Traction bronchiectasis indicates early fibrotic changes, placing this in the "fibrotic HP" category 2

Mediastinal Lymphadenopathy

• Mildly enlarged lymph nodes (14 x 10 mm) are compatible with HP as part of the inflammatory response 1
• This is not specific but supports an inflammatory/immunologic process

Diagnostic Confidence Level

Based on the 2021 CHEST guidelines 1 and 2020 ATS/JRS/ALAT guidelines 2, this CT pattern falls into the "Compatible with Nonfibrotic HP transitioning to Fibrotic HP" category because:

• Centrilobular nodules are present but distribution details aren't specified as "profuse and diffuse"
• Air-trapping is evident (volume loss)
• Early fibrotic changes exist (bronchiectasis)
• The pattern lacks the "three-density sign" that would make it "typical" fibrotic HP 2

Critical Next Steps

1. Detailed Exposure History (Mandatory)

Look specifically for:

• Bird exposure (pet birds, feather pillows, down comforters)
• Mold exposure (water damage, humidifiers, hot tubs)
• Occupational exposures (farming, metalworking fluids, isocyanates)
• Home environment (old buildings, ventilation systems)

The combination of clinical exposure history with these CT findings increases diagnostic confidence to 84-100% 1

2. Bronchoscopy with BAL and Transbronchial Biopsy

• BAL lymphocyte count >20% supports HP (though not required for diagnosis) 1
• Transbronchial biopsy increases diagnostic yield substantially when combined with BAL, particularly in fibrotic HP 1
• Look for: granulomas, giant cells, inflammatory bronchiolitis, or mononuclear cellular infiltrate 1
• In one study, TBB was diagnostic in 40% of HP cases and particularly valuable when BAL lymphocytes were <20% 1

3. Serum Precipitins/IgG Antibodies

• Test for specific antigens based on exposure history
• Positive results support but don't confirm HP; negative results don't exclude it

4. Pulmonary Function Tests

• Assess for restrictive pattern and DLCO reduction
• Helps stage disease severity and guide treatment urgency

Alternative Diagnoses to Exclude

While HP is most likely, consider:

Infectious Bronchopneumonitis

• The radiologist's interpretation mentions "broncho-pneumonitis"
• However, infectious causes (bacterial, viral, fungal, atypical organisms like Chlamydia pneumoniae) typically present with:
  • Acute symptoms (fever, productive cough)
  • More consolidative pattern rather than pure centrilobular nodules 3, 4
  • Tree-in-bud pattern more prominent than seen here 3
  • Would not explain chronic bronchiectasis
• If infection suspected, obtain sputum cultures and consider atypical pathogen testing 4

Organizing Pneumonia

• Can show patchy ground-glass opacities
• Typically lacks the centrilobular nodular pattern and air-trapping combination
• Usually more peripheral/subpleural distribution

Sarcoidosis

• Would show perilymphatic nodules (along bronchovascular bundles, interlobular septa, pleura), not centrilobular 5
• Lymphadenopathy would typically be more prominent (>15 mm)

Management Algorithm

If exposure identified + BAL/biopsy confirms HP:

1. Antigen avoidance (most critical intervention for morbidity/mortality)
2. Systemic corticosteroids if symptomatic or progressive (prednisone 0.5-1 mg/kg/day, taper over 6-12 months)
3. Consider antifibrotic therapy (nintedanib or pirfenidone) if fibrotic HP with progression despite steroids
4. Serial PFTs and CT monitoring every 3-6 months

If exposure not identified or diagnosis uncertain:

1. Proceed with bronchoscopy as above
2. Consider surgical lung biopsy if bronchoscopy non-diagnostic and clinical suspicion remains high 1
3. Multidisciplinary discussion (pulmonology, radiology, pathology)

Critical Pitfalls to Avoid

• Don't dismiss as simple "bronchopneumonitis" and treat with antibiotics alone—this delays HP diagnosis and allows progression to irreversible fibrosis
• Don't wait for "typical" HP pattern—this "compatible" pattern still warrants full workup 1
• Don't rely on normal BAL lymphocytes to exclude HP—TBB can still be diagnostic in 46% of cases with <20% BAL lymphocytes 1
• Don't ignore the bronchiectasis—this indicates chronicity and potential fibrotic progression requiring more aggressive management
• Early diagnosis is critical—fibrotic HP has significantly worse prognosis than nonfibrotic HP, with mortality implications if antigen exposure continues

The presence of early fibrotic changes (bronchiectasis) makes this a time-sensitive diagnosis requiring urgent workup to prevent progression to irreversible pulmonary fibrosis and associated mortality.